CSL LimitedASX: CSL

CSL to acquire Novartis influenza vaccine business

· Issued by CSL Limited

Filed with ASX · · 14 pages · English

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis’ global influenza vaccine business for US$275 million. The business will be combined with CSL’s subsidiary, bioCSL. Combining bioCSL’s existing influenza vaccine operations with the Novartis business will create the number two global player in the US$4 billion global influenza vaccine industry, with manufactu

CSL Limited on 6ix

Story so far

Earlier from CSL

Later from CSL

All CSL news releases